The pathophysiology of inorganic polyphosphates in inflammatory bowel disease.

The pathophysiology of inorganic polyphosphates in inflammatory bowel disease. - PoPhCED

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023079

Enrollment

220

Registered

2021-01-11

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HEALTHY VOLUNTEERS K50.9 K51.9 A04.8

Interventions

Group 1: Patients with Crohn's disease Phase 1: Case-Control Measurement of PoP concentrations in plasma, platelets and stools at point of diagnosis. Phase 2: Longitudinale Phase Measurement of P

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Written informed consent, pediatric patients suspicious for CED or bacterial intestinal infection or volunteers (healthy and normal clotting and aggregation tests)

Exclusion criteria

Exclusion criteria: missing written consent, anticoagulant therapy (e.g. Heparin) or antiplatelet therapy (e.g. Aspirin or Clopidogrel)

Design outcomes

Primary

Measure	Time frame
Primary outcome is the concentration of inorganic polyphosphates in plasma.	—

Secondary

Measure	Time frame
Secondary outcome is the levels of polyphosphates in platelets and stools.	—

Countries

Austria

Contacts

Public ContactHarald Haidl

Universitätsklinik für Kinder- und JugendheilkundeMedizinische Universität Graz

harald.haidl@medunigraz.at+4331638530008

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026